CoDx (CODX): Rega marang dodolan

High certification costs and CoPrime's patent protection create barriers for competitors, as confirmed by the P/S time series on the GURU.Markets system dynamic chart, where the current parameter equals 4.00. Risks are mitigated through the sale of PCR systems and technology licensing. Meanwhile, Co-Diagnostics, Inc. (CODX) management is actively expanding its international test portfolio, successfully commercializing its developments in the field of molecular diagnostics.

To objectively evaluate an issuer, it is essential for a manager to correlate the business's market value with its actual income stream. This multiple determines the price of one dollar of sales, making it possible to identify asset undervaluation or the risk of capital stagnation. The price-to-sales ratio trend reflects market expectations for future growth rates. For Co-Diagnostics, Inc. (CODX), this confirms stable post-pandemic demand for PCR technologies from laboratories.